Publication Name	World Journal of Ophthalmology
Manuscript ID	15585
Country	United States

Received	2014-11-29 12:58
Peer-Review Started	2014-11-29 13:43
To Make the First Decision	2014-12-12 17:31
Return for Revision	2014-12-18 10:44
Revised	2015-01-12 12:17
Second Decision	2015-02-26 17:36
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-03-05 18:18
Articles in Press	2015-03-05 18:19
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-04-27 16:05
Publish the Manuscript Online	2015-05-19 17:29

ISSN	2218-6239 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Ophthalmology
Manuscript Type	Minireviews
Article Title	Current understanding and management of aggressive posterior retinopathy of prematurity
Manuscript Source	Invited Manuscript
All Author List	Christine M Pulido and Polly A Quiram
Funding Agency and Grant Number
Corresponding Author	Polly A Quiram, MD, PhD, VitreoRetinal Surgery, P.A., 7760 France Ave S, Suite 310, Minneapolis, MN 55435, United States. pollyquiram@yahoo.com
Key Words	Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity; Photographic Screening for Retinopathy of Prematurity; Aggressive posterior retinopathy of prematurity; Retinopathy of prematurity; Intravitreal bevacizumab; Early Treatment of Retinopathy of Prematurity Study; Stanford University Network for Diagnosis of Retinopathy of Prematurity
Core Tip	Neonates with aggressive posterior retinopathy of prematurity often have unfavorable visual outcomes due to the aggressive and destructive nature of the disease. Treatment options, including laser and anti-vascular endothelial growth factor therapy can change the course of the disease, but both with potential side effects. Case studies and recommendations regarding the management of these complicated cases are reviewed.
Publish Date	2015-05-19 17:29
Citation	Pulido CM, Quiram PA. Current understanding and management of aggressive posterior retinopathy of prematurity. World J Ophthalmol 2015; 5(2): 73-79
URL	http://www.wjgnet.com/2218-6239/full/v5/i2/73.htm
DOI	http://dx.doi.org/10.5318/wjo.v5.i2.73

Full Article (PDF)	WJO-5-73.pdf
Full Article (Word)	WJO-5-73.doc
Manuscript File	15585-Review.docx
Answering Reviewers	15585-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	15585-Conflict-of-interest statement.pdf
Copyright License Agreement	15585-Copyright assignment.pdf
Peer-review Report	15585-Peer-review(s).pdf
Scientific Misconduct Check	15585-Scientific misconduct check.pdf
Scientific Editor Work List	15585-Scientific editor work list.pdf